Clinical Trials Logo

Clinical Trial Summary

Oral treatment with betaine is conventionally used for patients with inherited homocystinurias. These conditions include a first group of patients with a cystathionine β-synthase (CBS) deficiency and a second group of patients with remethylation defects. The aim of betaine therapy is to reduce level of total plasma homocysteine. Daily dosages and rhythm of administration proposed in the literature vary between 100 to 250 mg / kg / d in 2 to 4 doses. These dosages are not based on validated data and several publications mention much higher dosages particularly when total homocysteine is not controlled. These practices may be unnecessary or even detrimental given the fact that high doses of betaine could for example lead to secondary folate deficiency.


Clinical Trial Description

Oral treatment with betaine is conventionally used for patients with inherited homocystinurias. These conditions include a first group of patients with a cystathionine β-synthase (CBS) deficiency and a second group of patients with remethylation defects. The aim of betaine therapy is to reduce level of total plasma homocysteine. Daily dosages and rhythm of administration proposed in the literature vary between 100 to 250 mg / kg / d in 2 to 4 doses. These dosages are not based on validated data and several publications mention much higher dosages particularly when total homocysteine is not controlled. These practices may be unnecessary or even detrimental given the fact that high doses of betaine could for example lead to secondary folate deficiency. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02404337
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase Phase 2
Start date July 2015
Completion date February 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT05910151 - Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT00483314 - Homocystinuria: Treatment With N-Acetylcysteine Phase 2
Recruiting NCT05051657 - Evaluation of the Express Plus Range N/A
Completed NCT05462132 - Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers Phase 1
Completed NCT04021732 - Effects of Exercise on Metabolic Parameters in Classical Homocystinuria
Active, not recruiting NCT03406611 - Pegtibatinase as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) Phase 1/Phase 2
Completed NCT01192828 - Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine Phase 1/Phase 2
Completed NCT00004356 - Study of Homocysteine Metabolism in Homocystinuria N/A
Recruiting NCT06247085 - A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment Phase 3
Enrolling by invitation NCT06431893 - A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Phase 3